(S)-2-氨基-3-(4-乙基苯基)丙酸 | 4313-70-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-氨基-3-(4-乙基苯基)丙酸
• 英文名称: L-p-ethylphenylalanine
• 英文别名: (2S)-2-azaniumyl-3-(4-ethylphenyl)propanoate
• CAS: 4313-70-6
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: AWKDBHFQJATNBQ-JTQLQIEISA-N

物化性质

• 熔点：
  244-247 °C (decomp)
• 沸点：
  335.4±30.0 °C(Predicted)
• 密度：
  1.135±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  (S)-2-氨基-3-(4-乙基苯基)丙酸 在 氯化亚砜 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Substituted N-(3,5-Dichlorobenzenesulfonyl)-l-prolyl-phenylalanine analogues as potent VLA-4 antagonists

  摘要：

  A series of substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl- and alpha-methyl-L-prolyl-phenylalanine derivatives was prepared as VLA-4/VCAM antagonists. The compounds showed excellent potency with a wide variety of neutral, polar, electron withdrawing or donating groups on the phenylalanine ring (IC50 similar to I nM). Heteroaryl ring substitution for phenylalanine was also well tolerated. Pharmacokinetic studies in rat were performed on a representative set of compounds in both series. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00821-6
• 作为产物：
  描述：

  N-phenylacetyl-p-ethyl-DL-phenylalanine 生成 (S)-2-氨基-3-(4-乙基苯基)丙酸
  参考文献：
  名称：

  LEBL, M.;KROJIDLO, M.;FLEGEL, M.;BARTA, M.;VOJTISEK, V.;CULIK, K.

  摘要：

  DOI：

文献信息

• Phenylalanine Aminomutase-Catalyzed Addition of Ammonia to Substituted Cinnamic Acids: a Route to Enantiopure α- and β-Amino Acids
  作者：Wiktor Szymanski、Bian Wu、Barbara Weiner、Stefaan de Wildeman、Ben L. Feringa、Dick B. Janssen

  DOI：10.1021/jo901833y

  日期：2009.12.4

  approach is described for the synthesis of aromatic α- and β-amino acids that uses phenylalanine aminomutase to catalyze a highly enantioselective addition of ammonia to substituted cinnamic acids. The reaction has a broad scope and yields substituted α- and β-phenylalanines with excellent enantiomeric excess. The regioselectivity of the conversion is determined by substituents present at the aromatic ring

  描述了一种合成芳香族α-和β-氨基酸的方法，该方法使用苯丙氨酸氨基变位酶催化氨向取代肉桂酸的高度对映选择性加成。该反应具有广泛的范围，并产生具有优异对映体过量的取代的α-和β-苯丙氨酸。转化的区域选择性由芳环上存在的取代基决定。提出了一种酶活性位点的盒模型，该模型由取代基的疏水性对酶对各种底物的亲和力的影响得出。
• [EN] PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR<br/>[FR] MIMÉTIQUES DE PROTÉOGLYCANE POUR UNE CICATRISATION, UNE ANGIOGENÈSE ET UNE RÉPARATION VASCULAIRE AMÉLIORÉES
  申请人：UNIV CALIFORNIA

  公开号：WO2019195780A1

  公开（公告）日：2019-10-10

  The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

  本公开提供了促血管生成的蛋白聚糖类似物，可以提供一个暂时的、促血管生成的支架，支持组织再生，同时限制系统暴露于VEGF活性。这些类似物可以保护胶原基质免受快速降解，并与EPCs一起促进血管生成，以加速缺血性伤口愈合。例如，所提供的化合物可以从导管的末端输送，经过球囊扩张后涂覆暴露的胶原区域，防止血小板结合和血栓形成，支持从血液中捕获EPCs以促进再内皮化，减少晚期腔隙损失（内膜增生）。
• [EN] PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS<br/>[FR] PEPTIDES POUR L'ACTIVATION DE LA SIGNALISATION CELLULAIRE DANS DES CELLULES OSTÉOPROGÉNITRICES
  申请人：UNIV CALIFORNIA

  公开号：WO2020018941A1

  公开（公告）日：2020-01-23

  The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.

  本发明提供了肽类模拟配体的化合物和制药组合物。这些肽类模拟配体可以与膦酸盐药物结合。本发明的化合物和制药组合物由于其对于骨髓干细胞上的α4β1整合素和骨表面的特异性而可用于治疗骨质疏松症和促进骨生长。
• Bioactive peptides
  申请人：ALPHARMA AS

  公开号：US20030022821A1

  公开（公告）日：2003-01-30

  The present invention provides a modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and which has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin sequence, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing such peptides, pharmaceutical compositions containing such peptides and use of the peptides as medicaments, particularly as antibacterials or anti-tumoural agents.

  本发明提供一种改性乳铁蛋白肽，其具有细胞毒性，长度为7至25个氨基酸，含有三个或更多阳离子残基，并且与天然乳铁蛋白序列相比，具有一个或多个额外的笨重和亲脂氨基酸，以及其酯、酰胺、盐和环状衍生物，以及制备这些肽的方法、含有这些肽的药物组合物和将这些肽用作药物的用途，特别是作为抗菌或抗肿瘤剂。
• [EN] LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT<br/>[FR] CONJUGUÉS LLP2A-BISPHOSPHONATE POUR LE TRAITEMENT DE L'OSTÉOPOROSE
  申请人：UNIV CALIFORNIA

  公开号：WO2013032527A1

  公开（公告）日：2013-03-07

  The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.

  本发明提供了一种肽类模拟配体化合物和制药组合物，例如LLP2A，与双磷酸盐药物，例如阿伦膦酸，结合。本发明的化合物和制药组合物由于对间充质干细胞上的α4β1整合素和骨表面的特异性，对骨质疏松症的治疗和促进骨生长具有用处。